| __timestamp | Halozyme Therapeutics, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 241751000 |
| Thursday, January 1, 2015 | 29245000 | 322292000 |
| Friday, January 1, 2016 | 33206000 | 344320000 |
| Sunday, January 1, 2017 | 31152000 | 374644000 |
| Monday, January 1, 2018 | 10136000 | 1820000 |
| Tuesday, January 1, 2019 | 45546000 | 4000000 |
| Wednesday, January 1, 2020 | 43367000 | 12000000 |
| Friday, January 1, 2021 | 81413000 | 11000000 |
| Saturday, January 1, 2022 | 139304000 | 14000000 |
| Sunday, January 1, 2023 | 192361000 | 9133000 |
| Monday, January 1, 2024 | 159417000 | 11215000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, cost efficiency is paramount. From 2014 to 2023, Halozyme Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. have showcased contrasting strategies in managing their cost of revenue. Halozyme's cost of revenue surged by over 740% from 2014 to 2023, reflecting a strategic expansion and increased operational scale. In contrast, Ionis Pharmaceuticals experienced a dramatic 96% reduction in cost of revenue over the same period, indicating a shift towards more efficient processes or a change in business focus.
The year 2018 marked a pivotal point for Ionis, with costs plummeting to just 0.8% of their 2017 levels, while Halozyme's costs remained relatively stable until a sharp increase in 2022. These trends highlight the dynamic nature of cost management in the biotech sector, where strategic decisions can lead to significant financial transformations.
Cost of Revenue Comparison: Novo Nordisk A/S vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for AbbVie Inc. and Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Novartis AG and Halozyme Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Evotec SE's Expenses
Cost of Revenue Comparison: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: Ionis Pharmaceuticals, Inc. and Wave Life Sciences Ltd.
Ionis Pharmaceuticals, Inc. vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored